REGENXBIO(RGNX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - REGENXBIO ended the quarter on December 31, 2025, with cash equivalents and marketable securities of $241 million, a slight decrease from $245 million as of December 31, 2024 [18] - R&D expenses increased to $228 million for the year ended December 31, 2025, compared to $209 million in 2024, primarily due to pivotal trial execution and manufacturing costs [19] - Total annual revenue was reported at $170 million, which includes upfront license revenue and an increase in royalty revenue [19][20] Business Line Data and Key Metrics Changes - The RGX-202 program for Duchenne muscular dystrophy (DMD) showed strong enrollment and positive functional outcomes, with an average improvement of 7.4 compared to the recognized CTAP model at 18 months [11][12] - The RGX-314 franchise for wet AMD and diabetic retinopathy is advancing, with enrollment completed in pivotal studies ATMOSPHERE and ASCENT, and a 93% reduction in annualized anti-VEGF injection need reported [14][15] - The NAVIGATE pivotal study for diabetic retinopathy is set to begin patient dosing next quarter, triggering a $100 million milestone from AbbVie [9][15] Market Data and Key Metrics Changes - The company is focusing on large indications such as Duchenne, wet AMD, and diabetic retinopathy, which represent significant commercial opportunities [22] - The unmet need in the Duchenne community remains significant, with less than 1% of the global population having received an approved gene therapy [7] Company Strategy and Development Direction - REGENXBIO aims to transition from a late-stage development organization to a commercial entity by advancing its late-stage pipeline and focusing on execution [6][22] - The company is committed to addressing clinical holds for RGX-111 and RGX-121 while continuing to support the MPS community [10][21] - The strategy includes leveraging in-house manufacturing and partnerships to enhance the treatment landscape [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming pivotal readouts and the potential for accelerated approval pathways for RGX-202 [5][26] - The company is optimistic about its safety profile and the compelling data from its clinical trials, which are expected to support its regulatory submissions [28][37] - Management acknowledged the importance of ongoing dialogue with the FDA to ensure alignment on data analysis methods and submission expectations [90] Other Important Information - The company has received clinical hold letters for RGX-111 and RGX-121 but believes the requirements to remove the holds are addressable [9] - REGENXBIO's cash runway is expected to extend into early 2027, not including anticipated milestones and additional funds from collaborations [20][21] Q&A Session Summary Question: Concerns about control trials for DMD - Management expressed confidence in the design of the confirmatory study and the compelling data supporting their approach to accelerated approval [25][26] Question: Potential longer duration follow-up for FDA - Management indicated that they would have 12-month data on the pivotal dataset and that the confirmatory study would provide additional safety data [35][36] Question: Update on RGX-202 data presentation - Management confirmed that the upcoming presentation would include additional functional data and safety outcomes [60][61] Question: Safety profile for DMD - Management reported no cases of liver injury or thrombocytopenia in the RGX-202 study, highlighting a differentiated safety profile compared to existing therapies [69] Question: Heparan sulfate data in MPS I - Management acknowledged the importance of heparan sulfate measurements and indicated that they would provide more detailed results in response to the CRL [81][82]